Colossal Biosciences vs Karius
Side-by-side comparison of AI visibility scores, market position, and capabilities
Colossal Biosciences is the world's first de-extinction company; $555M raised, $10.2B decacorn valuation; targeting woolly mammoth embryos by 2026, dire wolves already created Mar 2025.
About
Colossal Biosciences is the world's first commercial de-extinction and genomic engineering company, applying CRISPR gene editing and synthetic biology to resurrect extinct species and restore ecological balance. Founded in 2021 by tech entrepreneur Ben Lamm and Harvard geneticist George Church, Colossal is simultaneously pursuing the de-extinction of the woolly mammoth, the Tasmanian thylacine, the dodo bird, the dire wolf, and the bluebuck antelope — building the scientific and technological infrastructure to produce living specimens of each. The company's Dallas, Texas headquarters anchors a multi-disciplinary team spanning computational biology, developmental biology, reproductive science, and conservation ecology.
Karius raised $409M total including a $100M Series C in May 2024; its genomic blood test detects 1,000+ pathogens at 400+ U.S. hospitals; launched Karius Focus BAL for pneumonia in April 2025.
About
Karius is a Redwood City, CA-based life sciences company founded in 2014 that developed the Karius Test — a single blood draw that uses next-generation sequencing and AI to detect over 1,000 pathogens (bacteria, fungi, viruses, parasites) in seriously ill patients. The test is used when conventional cultures and targeted diagnostics fail, providing clinicians at transplant centers, children''s hospitals, and ICUs with a comprehensive pathogen report within 24 hours.
AI Visibility Head-to-Head
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.